Caprion Pharmaceuticals Inc. announced on May 5, 2006 evening the filing of a preliminary prospectus with the securities regulatory authorities in each of the provinces in Canada in connection with a proposed initial public offering of its common shares.
TechFinance.ca
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
Matrix Surgical’s OmniPore Implants Cleared for Marketing
The company expects to launch additional variants in early 2019.
AbbVie, Novartis Reach Deal on Humira Biosimilar
AbbVie reported Humira sales of $18.4 billion in 2017.
FDAnews Drug Daily Bulletin
CAPRION PHARMACEUTICALS TO GO PUBLIC
May 10, 2006